Silence Therapeutics CEO Craig Tooman steps down
Source: SeekingAlpha
2025-12-15 09:06:24 ET
More on Silence Therapeutics
- Silence Therapeutics: Divesiran Targets High-Burden PV
- Seeking Alpha’s Quant Rating on Silence Therapeutics
- Historical earnings data for Silence Therapeutics
- Financial information for Silence Therapeutics
Read the full article on Seeking Alpha
For further details see:
Silence Therapeutics CEO Craig Tooman steps down
Silence Therapeutics Plc
NASDAQ: SLN
SLN Trading
8.86% G/L:
$5.53 Last:
49,153 Volume:
$5.44 Open:
SLN Latest News
SLN Stock Data
$207,324,000
44,881,200
58.7%
11
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
